-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: To investigate the hypothesis that recently approved selective inhibitors of nuclear export (SINE compounds) for the treatment of refractory plasma cell (PC) malignancies may have potential in the treatment of lupus
Methods: Female NZB/NZW mice were treated with the SINE compound KPT-350 or vehicle control
RESULTS: KPT-350 abolished murine lupus nephritis in the early and late stages of the disease and rapidly impaired the generation of autoreactive plasma cells in the germinal center (GC)
Conclusions: Collectively, the team's findings provide support for the therapeutic potential of selective nuclear export inhibitor compounds as they target several molecular and cellular pathways critical in lupus pathogenesis, including plasma cells produced autoantibodies
Source: Rangel-Moreno, J.